{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:13:39Z","timestamp":1753438419111,"version":"3.40.5"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Sofosbuvir\/velpatasvir (SOF\/VEL) is a combination of direct-acting antivirals with pan-genotypic activity that is used to treat chronic hepatitis C virus infection. This was a fixed-dose regimen. SOF is a nucleotide nonstructural 5B polymerase inhibitor and VEL is an nonstructural 5A inhibitor. Side effects of this agent on the endocrine system, particularly iatrogenic Cushing syndrome (ICS), are uncommon. Here, we present a case of ICS with significantly low serum adrenocorticotropic hormone and cortisol levels caused by SOF\/VEL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 49-year-old Asian woman with chronic hepatitis C and cirrhosis presented with a round face, fat thickening at the clavicle and back of the neck, mild facial edema, facial congestion, skin ulceration on the hands, central obesity, acne, and general status changes after 3 months of treatment with SOF\/VEL (400 mg\/dose, 1\/day).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient\u2019s serum adrenocorticotropic hormone and cortisol levels dropped significantly, and her normal rhythm vanished, with no visible aberrant lesions on computed tomography or across the abdomen. The patient was diagnosed with ICS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Symptoms improved after withdrawing SOF\/VEL and taking low-dose oral hydrocortisone. Thus, the SOF\/VEL was suspected to be an offender. To our knowledge, this is the first time that SOF\/VEL has been linked to ICS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Hepatologists and primary care physicians treating hepatitis C virus should be more aware of this uncommon adverse event so that direct-acting antiviral therapy can be stopped sooner if it recurs. The findings of this study emphasize the importance of collaboration between hepatologists and endocrinologists in co-management of complications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030294","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T14:04:05Z","timestamp":1672149845000},"page":"e30294","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A rare case report of iatrogenic Cushing syndrome caused by direct anti-hepatitis C virus therapy with sofosbuvir\/velpatasvir"],"prefix":"10.1097","volume":"101","author":[{"given":"Bo","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianling","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjie","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4626-9828","authenticated-orcid":false,"given":"Qinglong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1060028016668897","article-title":"Sofosbuvir\/velpatasvir: the first pangenotypic direct-acting antiviral combination for hepatitis C.","volume":"51","author":"Chahine","year":"2017","journal-title":"Ann Pharmacother"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12072-021-10158-x","article-title":"Sofosbuvir\/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol Int"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jgh.15324","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.","volume":"36","author":"Wong","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.13576","article-title":"Real-world efficacy and safety of 12-week sofosbuvir\/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.","volume":"51","author":"Takaoka","year":"2021","journal-title":"Hepatol Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/ijms18102201","article-title":"Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis.","volume":"18","author":"Paragliola","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/09546634.2012.755252","article-title":"Iatrogenic Cushing\u2019s syndrome and topical steroid therapy: case series and review of the literature.","volume":"25","author":"Decani","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts.","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","article-title":"Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.","volume":"54","author":"Takehara","year":"2019","journal-title":"J Gastroenterol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection.","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12876-021-01837-y","article-title":"Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:23:59Z","timestamp":1746336239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":11,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030294","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}